NCT06831058View on ClinicalTrials.gov

A Pilot Study of Efgartigimod for Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

PHASE2RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

May 1, 2028

Study Completion Date

May 1, 2028

Conditions
Immune-mediated Thrombotic Thrombocytopenic Purpura
Interventions
DRUG

efgartigimod

intravenous efgartigimod weekly with monitoring of ADAMTS13 activity for 8 weeks, followed by an observational period of 8 weeks or until treatment failure.

Trial Locations (1)

55455

RECRUITING

University of Minnesota, Minneapolis

All Listed Sponsors
lead

University of Minnesota

OTHER